322 related articles for article (PubMed ID: 10818026)
1. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.
Gray A; Raikou M; McGuire A; Fenn P; Stevens R; Cull C; Stratton I; Adler A; Holman R; Turner R
BMJ; 2000 May; 320(7246):1373-8. PubMed ID: 10818026
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
8. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
Palmer AJ; Sendi PP; Spinas GA
Schweiz Med Wochenschr; 2000 Jul; 130(27-28):1034-40. PubMed ID: 10953853
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial.
Simon J; Gray A; Clarke P; Wade A; Neil A; Farmer A;
BMJ; 2008 May; 336(7654):1177-80. PubMed ID: 18420663
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study.
Wake N; Hisashige A; Katayama T; Kishikawa H; Ohkubo Y; Sakai M; Araki E; Shichiri M
Diabetes Res Clin Pract; 2000 Jun; 48(3):201-10. PubMed ID: 10802159
[TBL] [Abstract][Full Text] [Related]
12. The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes.
Fonda SJ; Graham C; Munakata J; Powers JM; Price D; Vigersky RA
J Diabetes Sci Technol; 2016 Jul; 10(4):898-904. PubMed ID: 26843480
[TBL] [Abstract][Full Text] [Related]
13. Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial.
Multicentre Aneurysm Screening Study Group
BMJ; 2002 Nov; 325(7373):1135. PubMed ID: 12433761
[TBL] [Abstract][Full Text] [Related]
14. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63).
Gray A; Clarke P; Farmer A; Holman R;
BMJ; 2002 Oct; 325(7369):860. PubMed ID: 12386035
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
Xie X; Vondeling H
Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness analysis of neonatal extracorporeal membrane oxygenation based on four year results from the UK Collaborative ECMO Trial.
Petrou S; Edwards L;
Arch Dis Child Fetal Neonatal Ed; 2004 May; 89(3):F263-8. PubMed ID: 15102733
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin.
Cameron C; Coyle D; Ur E; Klarenbach S
CMAJ; 2010 Jan; 182(1):28-34. PubMed ID: 20026626
[TBL] [Abstract][Full Text] [Related]
18. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.
Huang ES; Shook M; Jin L; Chin MH; Meltzer DO
Diabetes Care; 2006 Feb; 29(2):259-64. PubMed ID: 16443870
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.
Petrou S; Bischof M; Bennett C; Elbourne D; Field D; McNally H
Pediatrics; 2006 May; 117(5):1640-9. PubMed ID: 16651318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
